Background: Systemic sclerosis (SSc) is a chronic fibrosing autoimmune disease which leads to severe musculoskeletal dysfunction, disability and contractures. Little is known on the type and extent of physical therapy (PT) prescribed to SSc patients in daily practice. Objectives: To determine the type and frequency of PT received by SSc patients. Methods: The data of 3430 clinically well defined SSc patients registered in the database of the German Network for Systemic Sclerosis were analyzed using SPSS. Results: 48,5% (1662/3430) of the patients were treated with PT. The most frequently used form of PT was lymphatic drainage (23,6%/876), followed by physical exercise therapy (22%/817) and paraffin wax bath (10,5%/389). About half of the patients (46,9%) received two or three different forms of PT simultaneously. The prescription of PT did not correlate with the SSc subtype, as 49,5% (503/1016) of dcSSc patients, 50,3% (850/1689) of lcSSc patients and 45,7% (143/313) of SSc-Overlap patients received PT. PT was significantly more often prescribed to patients with pulmonary fibrosis in 51,1% (617/1208), synovitis in 61,6% (299/485) and CK elevation in 61,1% (174/285) (p=0,001-0,029). PT did not correlate with the extent of skin fibrosis as measured by mRSS. Interestingly, patients with joint contractures (45,5%) (388/853) or tendon friction rubs (40,6%) (114/281) received significantly less often PT (p=0, 006/ 0, 045) . Comparing the prescription of PT during the initial period 2003-2008 (49,1%; 1937/3942) with the follow up period 2009-2013 (45,3%; 2217/4899) , a significant decrease of PT prescription was observed (p<0,001). Patterns of PT prescription differed significantly between medical subspecialties (p<0,005) i.e. rheumatologists, dermatologists. Conclusions: Although SSc is characterized by considerable disability and restriction of motion, less than 50% of patients received PT. The significant decrease in PT prescription during recent years may reflect lack of knowledge how to prescribe PT and more restrictive insurance regulations. Background: Systemic sclerosis (SSc) is a rare, debilitating connective tissue disease characterized by immunological alterations, vasculopathy and progressive skin and multiorgan fibrosis. The autoimmune dysregulation in SSc comprises lymphocyte activation that leads to autoantibody production, abnormal production of cytokines and chemokines, and impairment of the innate immunity. Recent research has shown that the T cell activation and especially T helper cells play an important role in the pathogenesis of SSc. Amongst them are the proinflammatory Th17 cells. Objectives: To investigate T-cell activation, the percentage of Th17 cells and the circulating cytokine profile in SSc. Methods: We enrolled a total of 24 SSc patients and 16 healthy controls in the study and divided the patients as having diffuse cutaneous SSc (dcSSc, n=13) or limited cutaneous SSc (lcSSc, n=11). Peripheral venous blood samples were collected from all subjects. We examined the percentage of activated T cells (unstimulated and upon stimulation with PHA-M) and of Th17 cells by flow cytometry in both patients and controls. We used ELISA to quantitate the serum levels of human IL-6, TGF-β1, and IL-17A. Results: We identified a decreased percentage of activated T cells (CD3+CD69+) in PHA-stimulated samples from SSc patients in comparison with healthy controls, p<0.001. However, we did not establish a correlation between the down-regulated CD3+CD69+ cells and the SSc phenotype. With regard to Th17 cells, our patients demonstrated increased percentage as opposed to controls, p=0.031. We detected up-regulated Th17 cells within the lcSSc subset against controls, p=0.025. However, no difference was found between dcSSc and lcSSc patients. Regarding the peripheral cytokine profile, we detected raised levels of IL-6, p<0.001, TGF-β1, p=0.02, and IL-17A, p<0.001 in patients when compared to controls. Furthermore, we found increased circulating TGF-β, IL-6 and IL-17A in the lcSSc subset versus healthy individuals, as it follows TGF-β1, p=0.031, IL-6, p<0.001, and IL-17A, p<0.001. Furthermore, circulating IL-17A was higher in lcSSc as opposed to dcSSc subset, p=0.008. Within the dcSSc phenotype, we detected raised levels of IL-17A and IL-6 versus controls: IL-17A, p<0.001, IL-6, p<0.001. Conclusions: Our results demonstrate down-regulated T-cell activation upon PHA-stimulation along with pronounced peripheral Th17 profile, and related cytokines in SSc patients, suggesting their implication in the pathogenesis of SSc. Background: Systemic sclerosis (SSc), one of the most complex connective tissue disease, is characterized by three pathogenic events namely, vascular damage, autoimmunity and fibroblast activation, leading to a widespread fibrosis of skin and internal organs (1,2). Previous studies showed that 1) carbamylation mainly affects structural proteins undergoing to a low turn-over rate, namely dermal skin and tendons-associated proteins; and that 2) carbamylated proteins accumulate in skin in an age-dependent manner, contributing to tissue alteration (3). Objectives: As dermis is a disease target and anti-carbamylated protein antibodies (anti-CarP Ab) have been reported in patients with SSc (4), we sought to evaluate any relationship between anti-CarP Ab and clinical parameters reflecting skin involvement in SSc. Methods: Serum samples and clinical data from 123 patients with SSc were collected. Anti-CarP Ab were detected by indirect ELISA, using carbamylated bovine serum albumin as the antigen. Serum Anti-CarP Ab levels were also measured in 41 healthy aged-matched individuals. Clinical data were retrieved as previously reported (5).
Results:
The mean serum levels of anti-CarP Ab did not statistically differ between healthy and SSc group. In SSc, Spearman analysis showed that antiCarP inversely correlated with the modified Rodnan skin score (RSS) (R= -0.325, p<0.001), independently of patients' age. Receiver operating characteristics (ROC) analysis identified the anti-CarP cutoff that best discriminated dichotomized clinical variables related to skin involvement. This cutoff that was employed to subdivide SSc patients into anti-CarP positive and anti-CarP negative patients. Three SSc skin-related clinical parameters were significantly different between groups: RSS (p=0.001), SI skin (p=0.002), and scleredema (p<0.001). A worse skin involvement was associated with low anti-CarP levels.
Conclusions:
The study shows that anti-CarP Ab serum level inversely associates to the severity of skin involvement in SSc patients. One possible mechanism to explain the inverse association is that the disease-dependent accumulation of carbamylated proteins in the skin may neutralize circulating anti-CarP Ab, thus contributing to their serum levels decrease. However, further investigation is needed to clarify this issue and to assess whether the levels anti-CarP Ab can be useful in the clinical setting of SSc. Background: Systemic sclerosis (SSc) is a chronic autoimmune disorder with cutaneous, vascular and immune cells abnormalities that lead to extensive cutaneous and visceral fibrosis with high morbidity and mortality. P-Selectin glycoprotein ligand-1 (PSGL-1) is the major ligand for P-selectin. PSGL-1 mediates the initial contacts with endothelial cells during extravasation to inflamed tissues or homing to several tissues in homeostatic conditions. In addition, PSGL-1/P-Selectin interaction contributes to the homeostasis of the immune system by generating regulatory T cells 1 . Importantly, the metalloprotease ADAM8 interacts with PSGL-1 and proteolytically processes it, what could be a regulatory mechanism to control the expression of PSGL-1 2 . Interestingly, mice lacking PSGL-1 develop a progressive SSc-like syndrome 3 . Objectives: To investigate whether PSGL-1 and ADAM8 expression on leukocytes could be implicated in the pathogenesis of SSc. Methods: PBLs from 47 SSc patients and 35 healthy donors were analyzed by flow cytometry. The percentage of cells expressing PSGL-1, HLA-DR and ADAM8, as well as the membrane (without cell permeabilization) and total (after cell permeabilization) expression were assessed for each leukocyte subset. For cell permeabilization, cells were incubated for 15 min at room temperature with a fixation/permeabilization solution. Positivity was stablished using isotype control antibodies. Comparisons between groups were analyzed with Student t tests or Mann-Whitney U test. For pairwise multiple comparisons one-way ANOVA with Tukey's post hoc test was applied (p<0.05, 95% CI). To analyze the possible contribution of PSGL-1, ADAM8 and HLA-DR to SSc pathogenesis, and to explore whether they could be used as biomarkers for SSc, we studied the influence of these molecules using a multivariate logistic regression model. Results: SSc patients showed increased expression of HLA-DR in antigen presenting cells (B cells, monocytes and dendritic cells), indicating a higher activation of these cells. PSGL-1 expression in B cells was decreased in SSc patients but increased in monocytes, dendritic cells (DC) and T cells. ADAM8 was increased in B and T lymphocytes, monocytes and DC from SSc patients. Overall, we have identified three variables that are associated with SSc: high percentage of ADAM8-expressing pDC, high PSGL-1 expression in cDC and high HLA-DR expression in CD16+ monocytes. Remarkably, highest PSGL-1 expression on conventional DC (cDC) and high levels of ADAM8 on plasmacytoid DC (pDC) associate with interstitial lung disease (ILD), one of the most severe SSc clinical manifestations, suggesting that PSGL-1 and ADAM8 could be prognostic markers of ILD. Conclusions: This study highlights that PSGL-1 and ADAM8 expression on DC, monocytes and lymphocytes could be implicated in SSc pathogenesis and particularly on DC might act as biomarkers for ILD. 
